Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label Study of SNX-5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label Study of SNX-5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; SNX 5422 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Esanex

    • Most Recent Events

    • 26 Jul 2018 Planned End Date changed from 1 Oct 2018 to 1 Jul 2018.
    • 26 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2018.
    • 26 Jul 2018 Planned initiation date changed from 1 Mar 2017 to 2 Feb 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top